Moderna and Merck's mRNA Cancer Vaccine Wins Phase 3 — But There's No Filing Date

Merck and Moderna just put the first Phase 3 win on the board for an individualized mRNA cancer therapy — and then refused to give anyone a filing date.

Regeneron's Pasatru clears the FDA at roughly one point four million dollars a year, Ultragenyx finally lands a gene therapy, Xspray takes another Complete Response Letter — and later, Moderna's forty-four billion dollar session. Let's get into it.

Welcome to The Pharma Closeout for Thursday, August twentieth. I'm Alex Mercer.

And I'm Maya Patel.

One thousand one hundred and thirty-seven patients. Merck and Moderna announced it yesterday.

And read the design before you read the headline. Two-to-one randomization, intismeran on top of KEYTRUDA — not against it. So what got tested was the increment on an adjuvant standard that already works. That's the hard version of this trial, and it's the version that's failed for a decade.

The setup is what makes it land. This program was carrying the credibility of the entire individualized-vaccine field. One readout reversed the premise.

Then say the part they didn't announce.

No filing timeline. Both companies said they'll "engage with regulatory authorities." That is not a submission date, and it isn't revenue.

OK, but I'd push back on reading that as regulatory caution. The constraint isn't the agency — it's the factory. Every dose is bespoke. You sequence a patient's tumor, you build that patient's therapy. Turnaround time and cost per patient aren't footnotes at commercial volume; they are the commercial model. You can have a positive Phase 3 and still not have a product anyone can ship.

I'll give you most of that. But separate the clocks. The regulatory clock runs on topline data. The manufacturing clock runs on capital expenditure, and they don't have to finish together — you file, and you scale into the label.

That works if the label is narrow. Here's what it runs into: resected Stage two B disease is not an academic-center population. It's largely community-treated, and bespoke manufacturing has never been demonstrated at community-oncology volume. So the recurrence-free survival benefit is real, and the thing it converts into first isn't prescriptions — it's an allocation queue.

Then the honest synthesis is that this stopped being a "does it work" story yesterday and became a "who gets it" story. And those get settled by plant capacity and site logistics, not by data. Competitive read: if you're running commercial strategy in melanoma or adjuvant oncology, don't model launch date. Model per-patient turnaround time — that's what caps the addressable population no matter what the label says.

The other thing I'm holding out for is overall survival. Recurrence-free was met, distant metastasis-free was met, and the full dataset still goes to a medical meeting before anyone sees a curve. Durability is what decides whether payers treat this as a defined adjuvant course or as an open-ended negotiation — and right now the entire field is trading on a press release.

Which is a decent handoff to the other bottleneck story today. Roche is putting seven hundred and fifty million dollars into doubling its Genentech site in Hillsboro, Oregon — a new fill-finish plant for drug-device combinations, prefilled syringes and auto-injectors, end-to-end.

Fill-finish for self-administered devices is the tell. That's a portfolio going home with the patient instead of into an infusion chair.

Roche is explicit that the point is flexibility as the portfolio shifts — they're buying optionality on device format, not just volume. But if you're modeling US injectable capacity, this is capacity that doesn't exist for five years. Everything between now and then belongs to whoever contracted early.

On the regulatory side — the FDA approved Regeneron's Pasatru, garetosmab, for fibrodysplasia ossificans progressiva, at an average annual per-patient list price of about one point four million dollars. The Phase 3 showed a ninety percent or greater reduction in new abnormal bone formations versus placebo over a year. But this isn't a rare-disease approval story. Roughly flat.

Three years alone in an indication and that's the number? That's not underpenetration. That's a market telling you it doesn't believe the drug.

Which is why the approval matters more than the price tag. The two haven't been tested head-to-head, but Sohonos was associated with less impact on bone growth — and here's the detail I'd flag: Regeneron's own program was slowed by a study pause after multiple trial participant deaths. The company investigated, concluded the treatment likely wasn't the cause, and pushed into late-stage testing. The agency cleared it anyway.

And the list price isn't really a price — it's a range. The company put the annual total anywhere from six hundred and ninety-three thousand to two point one million, depending on weight-based dosing.

So the payer fight isn't over one point four million. It's over where the dosing distribution actually lands in a population of about one in a million patients — and Regeneron gets to make that argument against an incumbent nobody has been enthusiastic about. Staying on the regulatory side: Ultragenyx won FDA approval for pariglasgene brecaparvovec, an AAV gene therapy for glycogen storage disease type one A. First gene therapy approval for the company, after prior FDA setbacks, and it landed ahead of an August twenty-third action date.

Ahead of the date. That's not nothing for a company with that history.

The part worth noticing is the effect size. The Phase 3 GlucoGene study showed forty-one percent. Both statistically significant — but the effect shrank as the trial got bigger, which is the ordinary fate of a small early signal. Approving on the pivotal number tells you this agency will take a smaller, honest patient-burden benefit in ultra-rare metabolic disease. That's a precedent worth borrowing if you're designing one.

Before we look ahead — the market reaction to INTerpath deserves its own beat. Moderna jumped as much as one hundred and seventy-seven percent on August nineteenth, adding roughly forty-four to forty-five billion dollars in market value in one session. Largest single-day gain in company history. The prior record was up twenty-seven point eight percent in February 2020 — the day the COVID story started.

The stock had fallen four straight years and was nearly ninety-four percent below its 2021 peak going in. That's not a rally. That's the market changing its mind about what kind of company it's looking at.

Short sellers took roughly five and a half billion dollars in paper losses on the day, per S3 Partners.

And the sell side can't agree on what it's now worth. Morgan Stanley raised its target to two hundred and nine dollars and stayed Equal Weight — a firm saying the price is fair and the story is unfinished at the same time. Barclays is modeling about three billion in peak melanoma sales by 2035.

That's the exposure. Before yesterday the stock discounted failure. Now it discounts a good chunk of success — so the medical-meeting presentation carries downside it simply didn't carry on Tuesday.

Looking ahead — the full INTerpath dataset at a medical meeting is the only catalyst that matters here, and there's still no date on it. Separately, Xspray held its call Thursday morning on the Dasynoc Complete Response Letter, with resubmission targeted before year-end.

And be precise about that letter, because it's the third since 2023 and none of it is about the molecule. The FDA raised no issues with the clinical data, the bioequivalence, or the stability. What it cites is manufacturing observations at contract manufacturer NerPharMa, plus a request for additional commercial-scale batch data on the dasatinib product. Xspray's version is bioequivalent at a thirty percent lower dose — that science has been settled for three years. The contract site hasn't been, and clinical strength doesn't fix a plant.

Which is the whole day in one line. Merck and Moderna, Xspray, Roche in Oregon — three completely different scales, one constraint. The molecule stopped being the bottleneck. The plant is the bottleneck.

It really is the through-line. I'll be watching for an INTerpath presentation slot to appear on a conference agenda — the day that date lands, the durability question stops being theoretical for everybody holding this stock. Have a good evening.

And that is your Pharma Closeout for Thursday, August twentieth — intismeran autogene's Phase 3, Moderna's forty-four billion dollar session, Pasatru against Sohonos, Ultragenyx's first gene therapy, and Roche putting seven hundred and fifty million into Oregon. Genuinely loaded day. Follow the show on Spotify, Apple Podcasts, or wherever you listen — tomorrow's briefing lands on its own.